nodes	percent_of_prediction	percent_of_DWPC	metapath
Idarubicin—breast cancer—ovarian cancer	0.161	1	CtDrD
Idarubicin—Epirubicin—ovarian cancer	0.126	0.519	CrCtD
Idarubicin—Doxorubicin—ovarian cancer	0.117	0.481	CrCtD
Idarubicin—Topoisomerase Inhibitors—Topotecan—ovarian cancer	0.0887	0.28	CiPCiCtD
Idarubicin—Anthracyclines—Epirubicin—ovarian cancer	0.0779	0.246	CiPCiCtD
Idarubicin—Anthracyclines—Doxorubicin—ovarian cancer	0.0721	0.227	CiPCiCtD
Idarubicin—Topoisomerase Inhibitors—Epirubicin—ovarian cancer	0.0407	0.128	CiPCiCtD
Idarubicin—Topoisomerase Inhibitors—Doxorubicin—ovarian cancer	0.0377	0.119	CiPCiCtD
Idarubicin—Valrubicin—Epirubicin—ovarian cancer	0.0269	0.173	CrCrCtD
Idarubicin—Daunorubicin—Epirubicin—ovarian cancer	0.0269	0.173	CrCrCtD
Idarubicin—Doxorubicin—Epirubicin—ovarian cancer	0.0269	0.173	CrCrCtD
Idarubicin—Epirubicin—Doxorubicin—ovarian cancer	0.0249	0.16	CrCrCtD
Idarubicin—Daunorubicin—Doxorubicin—ovarian cancer	0.0249	0.16	CrCrCtD
Idarubicin—Valrubicin—Doxorubicin—ovarian cancer	0.0249	0.16	CrCrCtD
Idarubicin—TOP2A—Epirubicin—ovarian cancer	0.022	0.27	CbGbCtD
Idarubicin—ABCC1—Epirubicin—ovarian cancer	0.0122	0.15	CbGbCtD
Idarubicin—ABCC1—Paclitaxel—ovarian cancer	0.012	0.148	CbGbCtD
Idarubicin—TOP2A—Doxorubicin—ovarian cancer	0.0117	0.144	CbGbCtD
Idarubicin—ABCC1—Docetaxel—ovarian cancer	0.0087	0.107	CbGbCtD
Idarubicin—ABCC1—Doxorubicin—ovarian cancer	0.00648	0.0796	CbGbCtD
Idarubicin—CYP2D6—Vinorelbine—ovarian cancer	0.00389	0.0478	CbGbCtD
Idarubicin—CYP2C9—Paclitaxel—ovarian cancer	0.00299	0.0367	CbGbCtD
Idarubicin—CYP2D6—Doxorubicin—ovarian cancer	0.00147	0.0181	CbGbCtD
Idarubicin—Daunorubicin—NR5A1—ovarian cancer	0.000558	0.626	CrCbGaD
Idarubicin—TOP2A—myometrium—ovarian cancer	0.000249	0.0947	CbGeAlD
Idarubicin—TOP2A—uterine cervix—ovarian cancer	0.000194	0.0737	CbGeAlD
Idarubicin—TOP2A—decidua—ovarian cancer	0.000185	0.0702	CbGeAlD
Idarubicin—TOP2A—endometrium—ovarian cancer	0.000175	0.0667	CbGeAlD
Idarubicin—TOP2A—Docetaxel—Paclitaxel—ovarian cancer	0.000168	0.235	CbGdCrCtD
Idarubicin—TOP2A—uterus—ovarian cancer	0.000162	0.0614	CbGeAlD
Idarubicin—ABCC1—myometrium—ovarian cancer	0.00015	0.057	CbGeAlD
Idarubicin—TOP2A—Irinotecan—Topotecan—ovarian cancer	0.000144	0.201	CbGdCrCtD
Idarubicin—Daunorubicin—CYP1B1—ovarian cancer	0.000143	0.161	CrCbGaD
Idarubicin—TOP2A—G0 and Early G1—RBL2—ovarian cancer	0.000143	0.0604	CbGpPWpGaD
Idarubicin—TOP2A—bone marrow—ovarian cancer	0.000137	0.0521	CbGeAlD
Idarubicin—TOP2A—female gonad—ovarian cancer	0.000132	0.0503	CbGeAlD
Idarubicin—TOP2A—vagina—ovarian cancer	0.000131	0.05	CbGeAlD
Idarubicin—TOP2A—testis—ovarian cancer	0.000117	0.0446	CbGeAlD
Idarubicin—ABCC1—uterine cervix—ovarian cancer	0.000117	0.0444	CbGeAlD
Idarubicin—Doxorubicin—CYP1B1—ovarian cancer	0.000116	0.13	CrCbGaD
Idarubicin—ABCC1—decidua—ovarian cancer	0.000111	0.0423	CbGeAlD
Idarubicin—TOP2A—Vindesine—Vinorelbine—ovarian cancer	0.000107	0.15	CbGdCrCtD
Idarubicin—ABCC1—endometrium—ovarian cancer	0.000106	0.0402	CbGeAlD
Idarubicin—ABCC1—uterus—ovarian cancer	9.74e-05	0.037	CbGeAlD
Idarubicin—TOP2A—lymph node—ovarian cancer	8.5e-05	0.0323	CbGeAlD
Idarubicin—TOP2A—Paclitaxel—Docetaxel—ovarian cancer	8.39e-05	0.117	CbGdCrCtD
Idarubicin—ABCC1—female gonad—ovarian cancer	7.96e-05	0.0303	CbGeAlD
Idarubicin—ABCC1—vagina—ovarian cancer	7.92e-05	0.0301	CbGeAlD
Idarubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—ovarian cancer	7.67e-05	0.0324	CbGpPWpGaD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	7.19e-05	0.0303	CbGpPWpGaD
Idarubicin—ABCC1—testis—ovarian cancer	7.06e-05	0.0268	CbGeAlD
Idarubicin—CYP2C9—female reproductive system—ovarian cancer	6.62e-05	0.0252	CbGeAlD
Idarubicin—TOP2A—G0 and Early G1—CCNE1—ovarian cancer	6.39e-05	0.027	CbGpPWpGaD
Idarubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—YAP1—ovarian cancer	6.31e-05	0.0266	CbGpPWpGaD
Idarubicin—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	5.94e-05	0.0251	CbGpPWpGaD
Idarubicin—TOP2A—Vincristine—Vinorelbine—ovarian cancer	5.77e-05	0.0807	CbGdCrCtD
Idarubicin—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	5.41e-05	0.0228	CbGpPWpGaD
Idarubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FASN—ovarian cancer	5.15e-05	0.0217	CbGpPWpGaD
Idarubicin—ABCC1—lymph node—ovarian cancer	5.12e-05	0.0195	CbGeAlD
Idarubicin—ABCC1—Irinotecan Pathway—APC—ovarian cancer	5.07e-05	0.0214	CbGpPWpGaD
Idarubicin—CYP2D6—female reproductive system—ovarian cancer	4.97e-05	0.0189	CbGeAlD
Idarubicin—CYP2D6—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	4.94e-05	0.0208	CbGpPWpGaD
Idarubicin—TOP2A—Vinblastine—Vinorelbine—ovarian cancer	4.64e-05	0.0649	CbGdCrCtD
Idarubicin—CYP2D6—female gonad—ovarian cancer	4.52e-05	0.0172	CbGeAlD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	4.3e-05	0.0181	CbGpPWpGaD
Idarubicin—Daunorubicin—ABCB1—ovarian cancer	4.11e-05	0.0461	CrCbGaD
Idarubicin—TOP2A—Gastric Cancer Network 1—APC—ovarian cancer	4.09e-05	0.0173	CbGpPWpGaD
Idarubicin—CYP2D6—testis—ovarian cancer	4.01e-05	0.0152	CbGeAlD
Idarubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—ovarian cancer	3.98e-05	0.0168	CbGpPWpGaD
Idarubicin—Malnutrition—Vinorelbine—ovarian cancer	3.72e-05	0.00105	CcSEcCtD
Idarubicin—Atrial fibrillation—Docetaxel—ovarian cancer	3.72e-05	0.00105	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—RBL2—ovarian cancer	3.71e-05	0.0157	CbGpPWpGaD
Idarubicin—Chest pain—Topotecan—ovarian cancer	3.7e-05	0.00105	CcSEcCtD
Idarubicin—Convulsion—Melphalan—ovarian cancer	3.69e-05	0.00104	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	3.68e-05	0.00104	CcSEcCtD
Idarubicin—Chest pain—Melphalan—ovarian cancer	3.62e-05	0.00102	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	3.6e-05	0.00102	CcSEcCtD
Idarubicin—Anaphylactic shock—Topotecan—ovarian cancer	3.55e-05	0.001	CcSEcCtD
Idarubicin—Hyperuricaemia—Epirubicin—ovarian cancer	3.53e-05	0.000997	CcSEcCtD
Idarubicin—Infection—Topotecan—ovarian cancer	3.53e-05	0.000997	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	3.51e-05	0.0148	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	3.51e-05	0.0148	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Melphalan—ovarian cancer	3.47e-05	0.000983	CcSEcCtD
Idarubicin—Thrombocytopenia—Topotecan—ovarian cancer	3.47e-05	0.000983	CcSEcCtD
Idarubicin—Extravasation—Doxorubicin—ovarian cancer	3.47e-05	0.000981	CcSEcCtD
Idarubicin—Decreased appetite—Chlorambucil—ovarian cancer	3.46e-05	0.00098	CcSEcCtD
Idarubicin—Ulcer—Epirubicin—ovarian cancer	3.46e-05	0.000978	CcSEcCtD
Idarubicin—Infection—Melphalan—ovarian cancer	3.45e-05	0.000976	CcSEcCtD
Idarubicin—Skin disorder—Topotecan—ovarian cancer	3.45e-05	0.000975	CcSEcCtD
Idarubicin—Anaemia—Vinorelbine—ovarian cancer	3.44e-05	0.000972	CcSEcCtD
Idarubicin—Pancytopenia—Paclitaxel—ovarian cancer	3.41e-05	0.000964	CcSEcCtD
Idarubicin—Thrombocytopenia—Melphalan—ovarian cancer	3.4e-05	0.000962	CcSEcCtD
Idarubicin—Anorexia—Topotecan—ovarian cancer	3.38e-05	0.000957	CcSEcCtD
Idarubicin—Skin disorder—Melphalan—ovarian cancer	3.37e-05	0.000954	CcSEcCtD
Idarubicin—Atrioventricular block—Epirubicin—ovarian cancer	3.37e-05	0.000954	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—TOP1—ovarian cancer	3.37e-05	0.0142	CbGpPWpGaD
Idarubicin—Neutropenia—Paclitaxel—ovarian cancer	3.36e-05	0.000949	CcSEcCtD
Idarubicin—Doxorubicin—ABCB1—ovarian cancer	3.34e-05	0.0374	CrCbGaD
Idarubicin—Blood uric acid increased—Epirubicin—ovarian cancer	3.33e-05	0.000942	CcSEcCtD
Idarubicin—Leukopenia—Vinorelbine—ovarian cancer	3.33e-05	0.000942	CcSEcCtD
Idarubicin—Anorexia—Melphalan—ovarian cancer	3.31e-05	0.000937	CcSEcCtD
Idarubicin—ABCC1—ABC-family proteins mediated transport—ABCB1—ovarian cancer	3.31e-05	0.0139	CbGpPWpGaD
Idarubicin—Dehydration—Docetaxel—ovarian cancer	3.27e-05	0.000926	CcSEcCtD
Idarubicin—Hyperuricaemia—Doxorubicin—ovarian cancer	3.26e-05	0.000923	CcSEcCtD
Idarubicin—Gastrointestinal pain—Chlorambucil—ovarian cancer	3.26e-05	0.000922	CcSEcCtD
Idarubicin—Ulcer—Doxorubicin—ovarian cancer	3.2e-05	0.000905	CcSEcCtD
Idarubicin—Urticaria—Chlorambucil—ovarian cancer	3.17e-05	0.000895	CcSEcCtD
Idarubicin—Chest pain—Vinorelbine—ovarian cancer	3.17e-05	0.000895	CcSEcCtD
Idarubicin—Acute coronary syndrome—Paclitaxel—ovarian cancer	3.16e-05	0.000892	CcSEcCtD
Idarubicin—Body temperature increased—Chlorambucil—ovarian cancer	3.15e-05	0.000891	CcSEcCtD
Idarubicin—Abdominal pain—Chlorambucil—ovarian cancer	3.15e-05	0.000891	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	3.14e-05	0.000889	CcSEcCtD
Idarubicin—Colitis—Epirubicin—ovarian cancer	3.14e-05	0.000888	CcSEcCtD
Idarubicin—Myocardial infarction—Paclitaxel—ovarian cancer	3.14e-05	0.000887	CcSEcCtD
Idarubicin—Atrioventricular block—Doxorubicin—ovarian cancer	3.12e-05	0.000883	CcSEcCtD
Idarubicin—Stomatitis—Paclitaxel—ovarian cancer	3.12e-05	0.000882	CcSEcCtD
Idarubicin—ABCC1—Arachidonic acid metabolism—CYP1B1—ovarian cancer	3.09e-05	0.013	CbGpPWpGaD
Idarubicin—Decreased appetite—Topotecan—ovarian cancer	3.08e-05	0.000872	CcSEcCtD
Idarubicin—Blood uric acid increased—Doxorubicin—ovarian cancer	3.08e-05	0.000872	CcSEcCtD
Idarubicin—Anaphylactic shock—Vinorelbine—ovarian cancer	3.04e-05	0.000858	CcSEcCtD
Idarubicin—Decreased appetite—Melphalan—ovarian cancer	3.02e-05	0.000854	CcSEcCtD
Idarubicin—Infection—Vinorelbine—ovarian cancer	3.02e-05	0.000853	CcSEcCtD
Idarubicin—Oesophagitis—Epirubicin—ovarian cancer	2.99e-05	0.000845	CcSEcCtD
Idarubicin—Thrombocytopenia—Vinorelbine—ovarian cancer	2.97e-05	0.000841	CcSEcCtD
Idarubicin—Neoplasm—Epirubicin—ovarian cancer	2.96e-05	0.000837	CcSEcCtD
Idarubicin—Skin disorder—Vinorelbine—ovarian cancer	2.95e-05	0.000834	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—PPP1CC—ovarian cancer	2.94e-05	0.0124	CbGpPWpGaD
Idarubicin—Hypersensitivity—Chlorambucil—ovarian cancer	2.94e-05	0.000831	CcSEcCtD
Idarubicin—Colitis—Doxorubicin—ovarian cancer	2.91e-05	0.000822	CcSEcCtD
Idarubicin—Gastrointestinal pain—Topotecan—ovarian cancer	2.9e-05	0.000821	CcSEcCtD
Idarubicin—Anorexia—Vinorelbine—ovarian cancer	2.89e-05	0.000818	CcSEcCtD
Idarubicin—Pancytopenia—Docetaxel—ovarian cancer	2.89e-05	0.000817	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—RSF1—ovarian cancer	2.89e-05	0.0122	CbGpPWpGaD
Idarubicin—Haemoglobin—Paclitaxel—ovarian cancer	2.89e-05	0.000817	CcSEcCtD
Idarubicin—Haemorrhage—Paclitaxel—ovarian cancer	2.87e-05	0.000813	CcSEcCtD
Idarubicin—Neutropenia—Docetaxel—ovarian cancer	2.85e-05	0.000805	CcSEcCtD
Idarubicin—Sepsis—Epirubicin—ovarian cancer	2.84e-05	0.000803	CcSEcCtD
Idarubicin—Urinary tract disorder—Paclitaxel—ovarian cancer	2.84e-05	0.000803	CcSEcCtD
Idarubicin—Urticaria—Topotecan—ovarian cancer	2.82e-05	0.000797	CcSEcCtD
Idarubicin—Urethral disorder—Paclitaxel—ovarian cancer	2.82e-05	0.000797	CcSEcCtD
Idarubicin—TOP2A—Daunorubicin—Epirubicin—ovarian cancer	2.81e-05	0.0393	CbGdCrCtD
Idarubicin—TOP2A—Doxorubicin—Epirubicin—ovarian cancer	2.81e-05	0.0393	CbGdCrCtD
Idarubicin—Abdominal pain—Topotecan—ovarian cancer	2.81e-05	0.000793	CcSEcCtD
Idarubicin—Body temperature increased—Topotecan—ovarian cancer	2.81e-05	0.000793	CcSEcCtD
Idarubicin—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	2.77e-05	0.0117	CbGpPWpGaD
Idarubicin—Oesophagitis—Doxorubicin—ovarian cancer	2.77e-05	0.000782	CcSEcCtD
Idarubicin—Urticaria—Melphalan—ovarian cancer	2.76e-05	0.000781	CcSEcCtD
Idarubicin—Phlebitis—Epirubicin—ovarian cancer	2.76e-05	0.00078	CcSEcCtD
Idarubicin—CYP2C9—Tamoxifen metabolism—CYP1B1—ovarian cancer	2.75e-05	0.0116	CbGpPWpGaD
Idarubicin—Thrombophlebitis—Epirubicin—ovarian cancer	2.74e-05	0.000776	CcSEcCtD
Idarubicin—Neoplasm—Doxorubicin—ovarian cancer	2.74e-05	0.000774	CcSEcCtD
Idarubicin—Diarrhoea—Chlorambucil—ovarian cancer	2.73e-05	0.000771	CcSEcCtD
Idarubicin—Hepatic function abnormal—Epirubicin—ovarian cancer	2.72e-05	0.000769	CcSEcCtD
Idarubicin—Acute coronary syndrome—Docetaxel—ovarian cancer	2.67e-05	0.000756	CcSEcCtD
Idarubicin—Flushing—Paclitaxel—ovarian cancer	2.67e-05	0.000754	CcSEcCtD
Idarubicin—Myocardial infarction—Docetaxel—ovarian cancer	2.66e-05	0.000752	CcSEcCtD
Idarubicin—Stomatitis—Docetaxel—ovarian cancer	2.64e-05	0.000748	CcSEcCtD
Idarubicin—Decreased appetite—Vinorelbine—ovarian cancer	2.64e-05	0.000746	CcSEcCtD
Idarubicin—TOP2A—Gastric Cancer Network 2—CTNNB1—ovarian cancer	2.64e-05	0.0111	CbGpPWpGaD
Idarubicin—Sepsis—Doxorubicin—ovarian cancer	2.63e-05	0.000743	CcSEcCtD
Idarubicin—Cardiac failure congestive—Epirubicin—ovarian cancer	2.62e-05	0.000741	CcSEcCtD
Idarubicin—Hypersensitivity—Topotecan—ovarian cancer	2.61e-05	0.000739	CcSEcCtD
Idarubicin—Angiopathy—Paclitaxel—ovarian cancer	2.61e-05	0.000737	CcSEcCtD
Idarubicin—TOP2A—Daunorubicin—Doxorubicin—ovarian cancer	2.6e-05	0.0364	CbGdCrCtD
Idarubicin—TOP2A—Epirubicin—Doxorubicin—ovarian cancer	2.6e-05	0.0364	CbGdCrCtD
Idarubicin—Immune system disorder—Paclitaxel—ovarian cancer	2.6e-05	0.000734	CcSEcCtD
Idarubicin—Chills—Paclitaxel—ovarian cancer	2.58e-05	0.000729	CcSEcCtD
Idarubicin—Arrhythmia—Paclitaxel—ovarian cancer	2.57e-05	0.000726	CcSEcCtD
Idarubicin—Hypersensitivity—Melphalan—ovarian cancer	2.56e-05	0.000724	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—HNF1B—ovarian cancer	2.55e-05	0.0108	CbGpPWpGaD
Idarubicin—Phlebitis—Doxorubicin—ovarian cancer	2.55e-05	0.000721	CcSEcCtD
Idarubicin—Alopecia—Paclitaxel—ovarian cancer	2.54e-05	0.000718	CcSEcCtD
Idarubicin—Hot flush—Epirubicin—ovarian cancer	2.54e-05	0.000718	CcSEcCtD
Idarubicin—Thrombophlebitis—Doxorubicin—ovarian cancer	2.54e-05	0.000718	CcSEcCtD
Idarubicin—Vomiting—Chlorambucil—ovarian cancer	2.53e-05	0.000717	CcSEcCtD
Idarubicin—Menopausal symptoms—Epirubicin—ovarian cancer	2.52e-05	0.000712	CcSEcCtD
Idarubicin—Hepatic function abnormal—Doxorubicin—ovarian cancer	2.51e-05	0.000711	CcSEcCtD
Idarubicin—Malnutrition—Paclitaxel—ovarian cancer	2.5e-05	0.000707	CcSEcCtD
Idarubicin—Gastrointestinal pain—Vinorelbine—ovarian cancer	2.48e-05	0.000702	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—SKP2—ovarian cancer	2.47e-05	0.0104	CbGpPWpGaD
Idarubicin—Haemoglobin—Docetaxel—ovarian cancer	2.45e-05	0.000692	CcSEcCtD
Idarubicin—Haemorrhage—Docetaxel—ovarian cancer	2.44e-05	0.000689	CcSEcCtD
Idarubicin—Diarrhoea—Topotecan—ovarian cancer	2.43e-05	0.000687	CcSEcCtD
Idarubicin—Cardiac failure congestive—Doxorubicin—ovarian cancer	2.42e-05	0.000685	CcSEcCtD
Idarubicin—Urticaria—Vinorelbine—ovarian cancer	2.41e-05	0.000682	CcSEcCtD
Idarubicin—Urinary tract disorder—Docetaxel—ovarian cancer	2.41e-05	0.00068	CcSEcCtD
Idarubicin—Abdominal pain—Vinorelbine—ovarian cancer	2.4e-05	0.000679	CcSEcCtD
Idarubicin—Body temperature increased—Vinorelbine—ovarian cancer	2.4e-05	0.000679	CcSEcCtD
Idarubicin—Urethral disorder—Docetaxel—ovarian cancer	2.39e-05	0.000675	CcSEcCtD
Idarubicin—Diarrhoea—Melphalan—ovarian cancer	2.38e-05	0.000672	CcSEcCtD
Idarubicin—ABCC1—S1P1 pathway—VEGFA—ovarian cancer	2.38e-05	0.01	CbGpPWpGaD
Idarubicin—Nausea—Chlorambucil—ovarian cancer	2.37e-05	0.00067	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	2.36e-05	0.00995	CbGpPWpGaD
Idarubicin—Hot flush—Doxorubicin—ovarian cancer	2.35e-05	0.000664	CcSEcCtD
Idarubicin—Menopausal symptoms—Doxorubicin—ovarian cancer	2.33e-05	0.000659	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	2.32e-05	0.00977	CbGpPWpGaD
Idarubicin—Anaemia—Paclitaxel—ovarian cancer	2.31e-05	0.000654	CcSEcCtD
Idarubicin—Flushing—Docetaxel—ovarian cancer	2.26e-05	0.000639	CcSEcCtD
Idarubicin—Vomiting—Topotecan—ovarian cancer	2.26e-05	0.000638	CcSEcCtD
Idarubicin—ABCC1—S1P1 pathway—MAPK3—ovarian cancer	2.25e-05	0.00948	CbGpPWpGaD
Idarubicin—Leukopenia—Paclitaxel—ovarian cancer	2.24e-05	0.000633	CcSEcCtD
Idarubicin—Rash—Topotecan—ovarian cancer	2.24e-05	0.000633	CcSEcCtD
Idarubicin—Hypersensitivity—Vinorelbine—ovarian cancer	2.24e-05	0.000632	CcSEcCtD
Idarubicin—Dermatitis—Topotecan—ovarian cancer	2.24e-05	0.000632	CcSEcCtD
Idarubicin—Headache—Topotecan—ovarian cancer	2.22e-05	0.000629	CcSEcCtD
Idarubicin—Angiopathy—Docetaxel—ovarian cancer	2.21e-05	0.000625	CcSEcCtD
Idarubicin—Vomiting—Melphalan—ovarian cancer	2.21e-05	0.000625	CcSEcCtD
Idarubicin—Dehydration—Epirubicin—ovarian cancer	2.21e-05	0.000625	CcSEcCtD
Idarubicin—Immune system disorder—Docetaxel—ovarian cancer	2.2e-05	0.000622	CcSEcCtD
Idarubicin—Rash—Melphalan—ovarian cancer	2.19e-05	0.00062	CcSEcCtD
Idarubicin—Dermatitis—Melphalan—ovarian cancer	2.19e-05	0.000619	CcSEcCtD
Idarubicin—Chills—Docetaxel—ovarian cancer	2.19e-05	0.000618	CcSEcCtD
Idarubicin—Arrhythmia—Docetaxel—ovarian cancer	2.18e-05	0.000615	CcSEcCtD
Idarubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	2.18e-05	0.00918	CbGpPWpGaD
Idarubicin—Convulsion—Paclitaxel—ovarian cancer	2.17e-05	0.000613	CcSEcCtD
Idarubicin—Alopecia—Docetaxel—ovarian cancer	2.15e-05	0.000609	CcSEcCtD
Idarubicin—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	2.14e-05	0.00903	CbGpPWpGaD
Idarubicin—ABCC1—S1P1 pathway—MAPK1—ovarian cancer	2.14e-05	0.00902	CbGpPWpGaD
Idarubicin—TOP2A—Gastric Cancer Network 2—MYC—ovarian cancer	2.14e-05	0.00901	CbGpPWpGaD
Idarubicin—Chest pain—Paclitaxel—ovarian cancer	2.13e-05	0.000602	CcSEcCtD
Idarubicin—Malnutrition—Docetaxel—ovarian cancer	2.12e-05	0.0006	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	2.12e-05	0.000598	CcSEcCtD
Idarubicin—Nausea—Topotecan—ovarian cancer	2.11e-05	0.000596	CcSEcCtD
Idarubicin—TOP2A—Gastric Cancer Network 2—EGFR—ovarian cancer	2.09e-05	0.00881	CbGpPWpGaD
Idarubicin—Diarrhoea—Vinorelbine—ovarian cancer	2.08e-05	0.000587	CcSEcCtD
Idarubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	2.07e-05	0.00872	CbGpPWpGaD
Idarubicin—Nausea—Melphalan—ovarian cancer	2.06e-05	0.000584	CcSEcCtD
Idarubicin—Dehydration—Doxorubicin—ovarian cancer	2.04e-05	0.000578	CcSEcCtD
Idarubicin—Anaphylactic shock—Paclitaxel—ovarian cancer	2.04e-05	0.000577	CcSEcCtD
Idarubicin—Infection—Paclitaxel—ovarian cancer	2.03e-05	0.000574	CcSEcCtD
Idarubicin—Shock—Paclitaxel—ovarian cancer	2.01e-05	0.000568	CcSEcCtD
Idarubicin—Thrombocytopenia—Paclitaxel—ovarian cancer	2e-05	0.000565	CcSEcCtD
Idarubicin—Skin disorder—Paclitaxel—ovarian cancer	1.98e-05	0.000561	CcSEcCtD
Idarubicin—Anaemia—Docetaxel—ovarian cancer	1.96e-05	0.000554	CcSEcCtD
Idarubicin—Pancytopenia—Epirubicin—ovarian cancer	1.95e-05	0.000551	CcSEcCtD
Idarubicin—Anorexia—Paclitaxel—ovarian cancer	1.95e-05	0.00055	CcSEcCtD
Idarubicin—Vomiting—Vinorelbine—ovarian cancer	1.93e-05	0.000546	CcSEcCtD
Idarubicin—Neutropenia—Epirubicin—ovarian cancer	1.92e-05	0.000543	CcSEcCtD
Idarubicin—Rash—Vinorelbine—ovarian cancer	1.91e-05	0.000541	CcSEcCtD
Idarubicin—Dermatitis—Vinorelbine—ovarian cancer	1.91e-05	0.000541	CcSEcCtD
Idarubicin—Headache—Vinorelbine—ovarian cancer	1.9e-05	0.000538	CcSEcCtD
Idarubicin—Leukopenia—Docetaxel—ovarian cancer	1.9e-05	0.000537	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CCND2—ovarian cancer	1.89e-05	0.00799	CbGpPWpGaD
Idarubicin—Convulsion—Docetaxel—ovarian cancer	1.84e-05	0.00052	CcSEcCtD
Idarubicin—Chest pain—Docetaxel—ovarian cancer	1.81e-05	0.000511	CcSEcCtD
Idarubicin—Pancytopenia—Doxorubicin—ovarian cancer	1.8e-05	0.00051	CcSEcCtD
Idarubicin—Nausea—Vinorelbine—ovarian cancer	1.8e-05	0.00051	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	1.79e-05	0.000507	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	1.79e-05	0.00754	CbGpPWpGaD
Idarubicin—Stomatitis—Epirubicin—ovarian cancer	1.78e-05	0.000505	CcSEcCtD
Idarubicin—Neutropenia—Doxorubicin—ovarian cancer	1.78e-05	0.000502	CcSEcCtD
Idarubicin—Decreased appetite—Paclitaxel—ovarian cancer	1.77e-05	0.000502	CcSEcCtD
Idarubicin—TOP2A—Gastric Cancer Network 2—TP53—ovarian cancer	1.75e-05	0.0074	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Docetaxel—ovarian cancer	1.73e-05	0.000489	CcSEcCtD
Idarubicin—Infection—Docetaxel—ovarian cancer	1.72e-05	0.000486	CcSEcCtD
Idarubicin—Shock—Docetaxel—ovarian cancer	1.7e-05	0.000481	CcSEcCtD
Idarubicin—Thrombocytopenia—Docetaxel—ovarian cancer	1.69e-05	0.000479	CcSEcCtD
Idarubicin—Skin disorder—Docetaxel—ovarian cancer	1.68e-05	0.000475	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	1.68e-05	0.00707	CbGpPWpGaD
Idarubicin—Gastrointestinal pain—Paclitaxel—ovarian cancer	1.67e-05	0.000472	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	1.66e-05	0.007	CbGpPWpGaD
Idarubicin—Haemoglobin—Epirubicin—ovarian cancer	1.65e-05	0.000467	CcSEcCtD
Idarubicin—Stomatitis—Doxorubicin—ovarian cancer	1.65e-05	0.000467	CcSEcCtD
Idarubicin—Anorexia—Docetaxel—ovarian cancer	1.65e-05	0.000467	CcSEcCtD
Idarubicin—Haemorrhage—Epirubicin—ovarian cancer	1.64e-05	0.000465	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—TYMS—ovarian cancer	1.63e-05	0.00687	CbGpPWpGaD
Idarubicin—Urinary tract disorder—Epirubicin—ovarian cancer	1.62e-05	0.000459	CcSEcCtD
Idarubicin—Urticaria—Paclitaxel—ovarian cancer	1.62e-05	0.000459	CcSEcCtD
Idarubicin—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	1.61e-05	0.00681	CbGpPWpGaD
Idarubicin—Abdominal pain—Paclitaxel—ovarian cancer	1.61e-05	0.000456	CcSEcCtD
Idarubicin—Body temperature increased—Paclitaxel—ovarian cancer	1.61e-05	0.000456	CcSEcCtD
Idarubicin—Urethral disorder—Epirubicin—ovarian cancer	1.61e-05	0.000455	CcSEcCtD
Idarubicin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	1.54e-05	0.00649	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	1.53e-05	0.00646	CbGpPWpGaD
Idarubicin—Haemoglobin—Doxorubicin—ovarian cancer	1.53e-05	0.000432	CcSEcCtD
Idarubicin—Flushing—Epirubicin—ovarian cancer	1.52e-05	0.000431	CcSEcCtD
Idarubicin—Haemorrhage—Doxorubicin—ovarian cancer	1.52e-05	0.00043	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—RAD51C—ovarian cancer	1.52e-05	0.0064	CbGpPWpGaD
Idarubicin—Decreased appetite—Docetaxel—ovarian cancer	1.5e-05	0.000425	CcSEcCtD
Idarubicin—Hypersensitivity—Paclitaxel—ovarian cancer	1.5e-05	0.000425	CcSEcCtD
Idarubicin—Urinary tract disorder—Doxorubicin—ovarian cancer	1.5e-05	0.000425	CcSEcCtD
Idarubicin—Angiopathy—Epirubicin—ovarian cancer	1.49e-05	0.000422	CcSEcCtD
Idarubicin—Urethral disorder—Doxorubicin—ovarian cancer	1.49e-05	0.000421	CcSEcCtD
Idarubicin—Immune system disorder—Epirubicin—ovarian cancer	1.48e-05	0.00042	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	1.48e-05	0.00626	CbGpPWpGaD
Idarubicin—Chills—Epirubicin—ovarian cancer	1.47e-05	0.000417	CcSEcCtD
Idarubicin—Arrhythmia—Epirubicin—ovarian cancer	1.47e-05	0.000415	CcSEcCtD
Idarubicin—Alopecia—Epirubicin—ovarian cancer	1.45e-05	0.000411	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	1.44e-05	0.00605	CbGpPWpGaD
Idarubicin—Malnutrition—Epirubicin—ovarian cancer	1.43e-05	0.000404	CcSEcCtD
Idarubicin—Gastrointestinal pain—Docetaxel—ovarian cancer	1.42e-05	0.0004	CcSEcCtD
Idarubicin—Flushing—Doxorubicin—ovarian cancer	1.41e-05	0.000399	CcSEcCtD
Idarubicin—Diarrhoea—Paclitaxel—ovarian cancer	1.4e-05	0.000395	CcSEcCtD
Idarubicin—Angiopathy—Doxorubicin—ovarian cancer	1.38e-05	0.00039	CcSEcCtD
Idarubicin—Immune system disorder—Doxorubicin—ovarian cancer	1.37e-05	0.000388	CcSEcCtD
Idarubicin—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	1.37e-05	0.00579	CbGpPWpGaD
Idarubicin—Body temperature increased—Docetaxel—ovarian cancer	1.37e-05	0.000387	CcSEcCtD
Idarubicin—Abdominal pain—Docetaxel—ovarian cancer	1.37e-05	0.000387	CcSEcCtD
Idarubicin—Chills—Doxorubicin—ovarian cancer	1.36e-05	0.000386	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle, Mitotic—RBL2—ovarian cancer	1.36e-05	0.00575	CbGpPWpGaD
Idarubicin—Arrhythmia—Doxorubicin—ovarian cancer	1.36e-05	0.000384	CcSEcCtD
Idarubicin—Alopecia—Doxorubicin—ovarian cancer	1.34e-05	0.00038	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—PPP1CC—ovarian cancer	1.33e-05	0.0056	CbGpPWpGaD
Idarubicin—Malnutrition—Doxorubicin—ovarian cancer	1.32e-05	0.000374	CcSEcCtD
Idarubicin—Anaemia—Epirubicin—ovarian cancer	1.32e-05	0.000374	CcSEcCtD
Idarubicin—Vomiting—Paclitaxel—ovarian cancer	1.3e-05	0.000367	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	1.3e-05	0.00548	CbGpPWpGaD
Idarubicin—Rash—Paclitaxel—ovarian cancer	1.29e-05	0.000364	CcSEcCtD
Idarubicin—Dermatitis—Paclitaxel—ovarian cancer	1.29e-05	0.000364	CcSEcCtD
Idarubicin—Leukopenia—Epirubicin—ovarian cancer	1.28e-05	0.000362	CcSEcCtD
Idarubicin—Headache—Paclitaxel—ovarian cancer	1.28e-05	0.000362	CcSEcCtD
Idarubicin—Hypersensitivity—Docetaxel—ovarian cancer	1.27e-05	0.000361	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	1.26e-05	0.0053	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	1.26e-05	0.0053	CbGpPWpGaD
Idarubicin—Convulsion—Epirubicin—ovarian cancer	1.24e-05	0.00035	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	1.23e-05	0.00521	CbGpPWpGaD
Idarubicin—Anaemia—Doxorubicin—ovarian cancer	1.22e-05	0.000346	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	1.22e-05	0.00516	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—RBL2—ovarian cancer	1.22e-05	0.00514	CbGpPWpGaD
Idarubicin—Chest pain—Epirubicin—ovarian cancer	1.22e-05	0.000344	CcSEcCtD
Idarubicin—Nausea—Paclitaxel—ovarian cancer	1.21e-05	0.000343	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	1.21e-05	0.000342	CcSEcCtD
Idarubicin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	1.2e-05	0.00505	CbGpPWpGaD
Idarubicin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	1.19e-05	0.005	CbGpPWpGaD
Idarubicin—TOP2A—Circadian rythm related genes—TYMS—ovarian cancer	1.19e-05	0.005	CbGpPWpGaD
Idarubicin—Leukopenia—Doxorubicin—ovarian cancer	1.18e-05	0.000335	CcSEcCtD
Idarubicin—Diarrhoea—Docetaxel—ovarian cancer	1.18e-05	0.000335	CcSEcCtD
Idarubicin—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	1.18e-05	0.00498	CbGpPWpGaD
Idarubicin—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	1.17e-05	0.00494	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Epirubicin—ovarian cancer	1.17e-05	0.00033	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	1.17e-05	0.00492	CbGpPWpGaD
Idarubicin—Infection—Epirubicin—ovarian cancer	1.16e-05	0.000328	CcSEcCtD
Idarubicin—Shock—Epirubicin—ovarian cancer	1.15e-05	0.000325	CcSEcCtD
Idarubicin—Convulsion—Doxorubicin—ovarian cancer	1.15e-05	0.000324	CcSEcCtD
Idarubicin—Thrombocytopenia—Epirubicin—ovarian cancer	1.14e-05	0.000323	CcSEcCtD
Idarubicin—Skin disorder—Epirubicin—ovarian cancer	1.13e-05	0.000321	CcSEcCtD
Idarubicin—Chest pain—Doxorubicin—ovarian cancer	1.13e-05	0.000319	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	1.12e-05	0.000316	CcSEcCtD
Idarubicin—Anorexia—Epirubicin—ovarian cancer	1.11e-05	0.000315	CcSEcCtD
Idarubicin—Vomiting—Docetaxel—ovarian cancer	1.1e-05	0.000311	CcSEcCtD
Idarubicin—Rash—Docetaxel—ovarian cancer	1.09e-05	0.000309	CcSEcCtD
Idarubicin—Dermatitis—Docetaxel—ovarian cancer	1.09e-05	0.000308	CcSEcCtD
Idarubicin—Headache—Docetaxel—ovarian cancer	1.08e-05	0.000307	CcSEcCtD
Idarubicin—Anaphylactic shock—Doxorubicin—ovarian cancer	1.08e-05	0.000305	CcSEcCtD
Idarubicin—Infection—Doxorubicin—ovarian cancer	1.07e-05	0.000303	CcSEcCtD
Idarubicin—Shock—Doxorubicin—ovarian cancer	1.06e-05	0.000301	CcSEcCtD
Idarubicin—Thrombocytopenia—Doxorubicin—ovarian cancer	1.06e-05	0.000299	CcSEcCtD
Idarubicin—Skin disorder—Doxorubicin—ovarian cancer	1.05e-05	0.000297	CcSEcCtD
Idarubicin—Anorexia—Doxorubicin—ovarian cancer	1.03e-05	0.000291	CcSEcCtD
Idarubicin—Nausea—Docetaxel—ovarian cancer	1.03e-05	0.000291	CcSEcCtD
Idarubicin—Decreased appetite—Epirubicin—ovarian cancer	1.01e-05	0.000287	CcSEcCtD
Idarubicin—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	9.7e-06	0.00409	CbGpPWpGaD
Idarubicin—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	9.61e-06	0.00406	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	9.59e-06	0.00404	CbGpPWpGaD
Idarubicin—Gastrointestinal pain—Epirubicin—ovarian cancer	9.54e-06	0.00027	CcSEcCtD
Idarubicin—Decreased appetite—Doxorubicin—ovarian cancer	9.39e-06	0.000266	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	9.35e-06	0.00395	CbGpPWpGaD
Idarubicin—Urticaria—Epirubicin—ovarian cancer	9.27e-06	0.000262	CcSEcCtD
Idarubicin—Abdominal pain—Epirubicin—ovarian cancer	9.23e-06	0.000261	CcSEcCtD
Idarubicin—Body temperature increased—Epirubicin—ovarian cancer	9.23e-06	0.000261	CcSEcCtD
Idarubicin—ABCC1—Disease—HSD17B6—ovarian cancer	9.14e-06	0.00386	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—SKP2—ovarian cancer	9.06e-06	0.00382	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	9.06e-06	0.00382	CbGpPWpGaD
Idarubicin—ABCC1—Transmembrane transport of small molecules—AQP3—ovarian cancer	8.96e-06	0.00378	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	8.86e-06	0.00374	CbGpPWpGaD
Idarubicin—Gastrointestinal pain—Doxorubicin—ovarian cancer	8.83e-06	0.00025	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	8.6e-06	0.00363	CbGpPWpGaD
Idarubicin—Hypersensitivity—Epirubicin—ovarian cancer	8.6e-06	0.000243	CcSEcCtD
Idarubicin—ABCC1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	8.59e-06	0.00362	CbGpPWpGaD
Idarubicin—Urticaria—Doxorubicin—ovarian cancer	8.58e-06	0.000243	CcSEcCtD
Idarubicin—Abdominal pain—Doxorubicin—ovarian cancer	8.54e-06	0.000241	CcSEcCtD
Idarubicin—Body temperature increased—Doxorubicin—ovarian cancer	8.54e-06	0.000241	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—ovarian cancer	8.2e-06	0.00346	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—MLH1—ovarian cancer	8.2e-06	0.00346	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—SKP2—ovarian cancer	8.1e-06	0.00342	CbGpPWpGaD
Idarubicin—Diarrhoea—Epirubicin—ovarian cancer	7.99e-06	0.000226	CcSEcCtD
Idarubicin—Hypersensitivity—Doxorubicin—ovarian cancer	7.96e-06	0.000225	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	7.68e-06	0.00324	CbGpPWpGaD
Idarubicin—Vomiting—Epirubicin—ovarian cancer	7.42e-06	0.00021	CcSEcCtD
Idarubicin—Diarrhoea—Doxorubicin—ovarian cancer	7.39e-06	0.000209	CcSEcCtD
Idarubicin—Rash—Epirubicin—ovarian cancer	7.36e-06	0.000208	CcSEcCtD
Idarubicin—Dermatitis—Epirubicin—ovarian cancer	7.35e-06	0.000208	CcSEcCtD
Idarubicin—Headache—Epirubicin—ovarian cancer	7.31e-06	0.000207	CcSEcCtD
Idarubicin—ABCC1—Disease—CHMP4C—ovarian cancer	7.31e-06	0.00308	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	7.04e-06	0.00297	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—NME2—ovarian cancer	7e-06	0.00296	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CCND2—ovarian cancer	6.95e-06	0.00293	CbGpPWpGaD
Idarubicin—Nausea—Epirubicin—ovarian cancer	6.93e-06	0.000196	CcSEcCtD
Idarubicin—Vomiting—Doxorubicin—ovarian cancer	6.87e-06	0.000194	CcSEcCtD
Idarubicin—Rash—Doxorubicin—ovarian cancer	6.81e-06	0.000193	CcSEcCtD
Idarubicin—Dermatitis—Doxorubicin—ovarian cancer	6.8e-06	0.000192	CcSEcCtD
Idarubicin—ABCC1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	6.79e-06	0.00286	CbGpPWpGaD
Idarubicin—Headache—Doxorubicin—ovarian cancer	6.77e-06	0.000191	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—CHEK2—ovarian cancer	6.63e-06	0.0028	CbGpPWpGaD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—MYC—ovarian cancer	6.58e-06	0.00278	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	6.55e-06	0.00276	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	6.52e-06	0.00275	CbGpPWpGaD
Idarubicin—Nausea—Doxorubicin—ovarian cancer	6.42e-06	0.000181	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	6.39e-06	0.00269	CbGpPWpGaD
Idarubicin—ABCC1—Disease—BCL9—ovarian cancer	6.34e-06	0.00267	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	6.22e-06	0.00262	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—BRCA1—ovarian cancer	6.21e-06	0.00262	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—CCND2—ovarian cancer	6.21e-06	0.00262	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	6.16e-06	0.0026	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CCNE1—ovarian cancer	6.08e-06	0.00257	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	6e-06	0.00253	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—TYMS—ovarian cancer	5.98e-06	0.00252	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	5.94e-06	0.00251	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—PPP2R1A—ovarian cancer	5.86e-06	0.00247	CbGpPWpGaD
Idarubicin—TOP2A—Circadian rythm related genes—PTEN—ovarian cancer	5.76e-06	0.00243	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—BRCA2—ovarian cancer	5.62e-06	0.00237	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—CCNE1—ovarian cancer	5.44e-06	0.0023	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	5.42e-06	0.00229	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—BIRC5—ovarian cancer	5.37e-06	0.00227	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—TYMS—ovarian cancer	5.34e-06	0.00225	CbGpPWpGaD
Idarubicin—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	5.15e-06	0.00217	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	5.13e-06	0.00216	CbGpPWpGaD
Idarubicin—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	5.11e-06	0.00215	CbGpPWpGaD
Idarubicin—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	5.08e-06	0.00214	CbGpPWpGaD
Idarubicin—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	5.04e-06	0.00212	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	4.99e-06	0.0021	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	4.88e-06	0.00206	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	4.88e-06	0.00206	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.84e-06	0.00204	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—BIRC5—ovarian cancer	4.81e-06	0.00203	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PPP1CC—ovarian cancer	4.71e-06	0.00199	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—TERT—ovarian cancer	4.66e-06	0.00196	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	4.61e-06	0.00194	CbGpPWpGaD
Idarubicin—ABCC1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.53e-06	0.00191	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—CYTB—ovarian cancer	4.51e-06	0.0019	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.41e-06	0.00186	CbGpPWpGaD
Idarubicin—ABCC1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.38e-06	0.00185	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	4.23e-06	0.00179	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	4.09e-06	0.00173	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—BRIP1—ovarian cancer	3.95e-06	0.00166	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PPP1CC—ovarian cancer	3.95e-06	0.00166	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	3.94e-06	0.00166	CbGpPWpGaD
Idarubicin—TOP2A—Circadian rythm related genes—TP53—ovarian cancer	3.93e-06	0.00166	CbGpPWpGaD
Idarubicin—TOP2A—Circadian rythm related genes—IL6—ovarian cancer	3.6e-06	0.00152	CbGpPWpGaD
Idarubicin—ABCC1—Disease—HDAC6—ovarian cancer	3.57e-06	0.00151	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.46e-06	0.00146	CbGpPWpGaD
Idarubicin—ABCC1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.45e-06	0.00146	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	3.15e-06	0.00133	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—NME2—ovarian cancer	3.14e-06	0.00132	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—NME2—ovarian cancer	3.11e-06	0.00131	CbGpPWpGaD
Idarubicin—ABCC1—Disease—XIAP—ovarian cancer	3.1e-06	0.00131	CbGpPWpGaD
Idarubicin—ABCC1—Disease—SMARCA4—ovarian cancer	3.02e-06	0.00127	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CCND1—ovarian cancer	3.01e-06	0.00127	CbGpPWpGaD
Idarubicin—ABCC1—Disease—EREG—ovarian cancer	2.94e-06	0.00124	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.87e-06	0.00121	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—CDKN1B—ovarian cancer	2.82e-06	0.00119	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—CCND1—ovarian cancer	2.69e-06	0.00114	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—YAP1—ovarian cancer	2.65e-06	0.00112	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.64e-06	0.00111	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.62e-06	0.0011	CbGpPWpGaD
Idarubicin—ABCC1—Disease—FASN—ovarian cancer	2.58e-06	0.00109	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PARP1—ovarian cancer	2.56e-06	0.00108	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—MAPK3—ovarian cancer	2.48e-06	0.00105	CbGpPWpGaD
Idarubicin—ABCC1—Disease—SLC2A1—ovarian cancer	2.45e-06	0.00103	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—MYC—ovarian cancer	2.41e-06	0.00102	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—MAPK1—ovarian cancer	2.36e-06	0.000996	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.3e-06	0.000971	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—MAPK3—ovarian cancer	2.22e-06	0.000936	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—MYC—ovarian cancer	2.16e-06	0.000911	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—FASN—ovarian cancer	2.16e-06	0.00091	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.15e-06	0.000908	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—SLC5A5—ovarian cancer	2.12e-06	0.000895	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—MAPK1—ovarian cancer	2.11e-06	0.000891	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PPP2R1A—ovarian cancer	2.08e-06	0.000878	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—SLC2A1—ovarian cancer	2.05e-06	0.000865	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—CYTB—ovarian cancer	2.02e-06	0.000854	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.01e-06	0.000847	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—CYTB—ovarian cancer	2.01e-06	0.000846	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—CYP1B1—ovarian cancer	1.96e-06	0.000829	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.96e-06	0.000827	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—TP53—ovarian cancer	1.77e-06	0.000748	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PPP1CC—ovarian cancer	1.77e-06	0.000746	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—BRIP1—ovarian cancer	1.77e-06	0.000746	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.75e-06	0.00074	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.75e-06	0.00074	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PPP2R1A—ovarian cancer	1.74e-06	0.000735	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.73e-06	0.000732	CbGpPWpGaD
Idarubicin—ABCC1—Disease—TERT—ovarian cancer	1.65e-06	0.000697	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—ABCB1—ovarian cancer	1.62e-06	0.000683	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—TYMS—ovarian cancer	1.59e-06	0.00067	CbGpPWpGaD
Idarubicin—ABCC1—Disease—CAV1—ovarian cancer	1.53e-06	0.000645	CbGpPWpGaD
Idarubicin—ABCC1—Disease—IL6ST—ovarian cancer	1.45e-06	0.000611	CbGpPWpGaD
Idarubicin—ABCC1—Disease—APC—ovarian cancer	1.39e-06	0.000588	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—CAV1—ovarian cancer	1.28e-06	0.00054	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.28e-06	0.000539	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PIK3CD—ovarian cancer	1.22e-06	0.000517	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.22e-06	0.000516	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—YAP1—ovarian cancer	1.19e-06	0.0005	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—YAP1—ovarian cancer	1.18e-06	0.000496	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PIK3CG—ovarian cancer	1.17e-06	0.000492	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.16e-06	0.000491	CbGpPWpGaD
Idarubicin—ABCC1—Disease—ERBB2—ovarian cancer	1.08e-06	0.000456	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PIK3CB—ovarian cancer	1.07e-06	0.00045	CbGpPWpGaD
Idarubicin—ABCC1—Disease—MTOR—ovarian cancer	1.07e-06	0.00045	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PIK3CD—ovarian cancer	1.03e-06	0.000433	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.02e-06	0.000432	CbGpPWpGaD
Idarubicin—ABCC1—Disease—CDKN1B—ovarian cancer	1e-06	0.000422	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—FASN—ovarian cancer	9.67e-07	0.000408	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—FASN—ovarian cancer	9.59e-07	0.000404	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—SLC5A5—ovarian cancer	9.51e-07	0.000401	CbGpPWpGaD
Idarubicin—ABCC1—Disease—CTNNB1—ovarian cancer	9.46e-07	0.000399	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—SLC5A5—ovarian cancer	9.43e-07	0.000398	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PTEN—ovarian cancer	9.22e-07	0.000389	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—SLC2A1—ovarian cancer	9.19e-07	0.000388	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—SLC2A1—ovarian cancer	9.11e-07	0.000384	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PIK3CB—ovarian cancer	8.94e-07	0.000377	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.92e-07	0.000376	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—CYP1B1—ovarian cancer	8.81e-07	0.000372	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—CYP1B1—ovarian cancer	8.73e-07	0.000368	CbGpPWpGaD
Idarubicin—ABCC1—Disease—STAT3—ovarian cancer	8.25e-07	0.000348	CbGpPWpGaD
Idarubicin—ABCC1—Disease—NRAS—ovarian cancer	8.23e-07	0.000347	CbGpPWpGaD
Idarubicin—ABCC1—Disease—MAPK3—ovarian cancer	7.88e-07	0.000332	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	7.81e-07	0.00033	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	7.74e-07	0.000327	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PTEN—ovarian cancer	7.72e-07	0.000326	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.71e-07	0.000325	CbGpPWpGaD
Idarubicin—ABCC1—Disease—MYC—ovarian cancer	7.66e-07	0.000323	CbGpPWpGaD
Idarubicin—ABCC1—Disease—MAPK1—ovarian cancer	7.5e-07	0.000316	CbGpPWpGaD
Idarubicin—ABCC1—Disease—EGFR—ovarian cancer	7.49e-07	0.000316	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—ABCB1—ovarian cancer	7.25e-07	0.000306	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—ABCB1—ovarian cancer	7.19e-07	0.000303	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—TYMS—ovarian cancer	7.12e-07	0.000301	CbGpPWpGaD
Idarubicin—ABCC1—Disease—KRAS—ovarian cancer	7.08e-07	0.000299	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—TYMS—ovarian cancer	7.06e-07	0.000298	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PIK3CA—ovarian cancer	6.5e-07	0.000274	CbGpPWpGaD
Idarubicin—ABCC1—Disease—HRAS—ovarian cancer	6.02e-07	0.000254	CbGpPWpGaD
Idarubicin—ABCC1—Disease—IL6—ovarian cancer	5.76e-07	0.000243	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—CAV1—ovarian cancer	5.74e-07	0.000242	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—CAV1—ovarian cancer	5.69e-07	0.00024	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PIK3CA—ovarian cancer	5.45e-07	0.00023	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.44e-07	0.000229	CbGpPWpGaD
Idarubicin—ABCC1—Disease—AKT1—ovarian cancer	5.31e-07	0.000224	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PIK3CG—ovarian cancer	5.23e-07	0.000221	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PIK3CG—ovarian cancer	5.18e-07	0.000219	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PIK3CD—ovarian cancer	4.6e-07	0.000194	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PIK3CD—ovarian cancer	4.56e-07	0.000192	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—AKT1—ovarian cancer	4.45e-07	0.000188	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.01e-07	0.000169	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PIK3CB—ovarian cancer	3.97e-07	0.000168	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PTEN—ovarian cancer	3.46e-07	0.000146	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PTEN—ovarian cancer	3.43e-07	0.000145	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.44e-07	0.000103	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.42e-07	0.000102	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—AKT1—ovarian cancer	2e-07	8.42e-05	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—AKT1—ovarian cancer	1.98e-07	8.34e-05	CbGpPWpGaD
